Combination Antioxidant/NSAID Therapies and Oral/Topical Ocular Delivery Modes for Prevention of Oxygen-Induced Retinopathy in a Rat Model
Given the complexity of oxygen-induced retinopathy (OIR), we tested the hypothesis that combination therapies and modes of administration would synergistically optimize efficacy for prevention of OIR. Newborn rats were exposed to neonatal intermittent hypoxia (IH) from the first day of life (P0) until P14 during which they received: (1) oral glutathione nanoparticles (nGSH) with topical ocular phosphate buffered saline (PBS); (2) nGSH with topical ocular Acuvail (ACV); (3) oral coenzyme Q10 (CoQ10) + ACV; (4) oral omega 3 polyunsaturated fatty acids (n-3 PUFAs) + ACV; (5) CoQ10 + n-3 PUFAs + PBS; or (6) CoQ10 + n-3 PUFAs + ACV. Treated groups raised in room air (RA) served as controls. At P14, pups were placed in RA with no treatment until P21. Retinal vascular pathology, ocular angiogenesis biomarkers, histopathology, and morphometry were determined. All combination treatments in IH resulted in the most beneficial retinal outcomes consistent with suppression of angiogenesis growth factors during reoxygenation/reperfusion and no significant adverse effects on somatic growth. nGSH + PBS also reversed IH-induced retinopathy, but had negative effects on growth. Simultaneously targeting oxidants, inflammation, and poor growth mitigates the damaging effects of neonatal IH on the developing retina. Therapeutic synergy with combination delivery methods enhance individual attributes and simultaneously target multiple pathways involved in complex diseases such as OIR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nutrients - 12(2020), 7 vom: 03. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beharry, Kay D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.02.2021 Date Revised 24.02.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/nu12071980 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312127278 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312127278 | ||
| 003 | DE-627 | ||
| 005 | 20231225143738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/nu12071980 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312127278 | ||
| 035 | |a (NLM)32635350 | ||
| 035 | |a (PII)E1980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beharry, Kay D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination Antioxidant/NSAID Therapies and Oral/Topical Ocular Delivery Modes for Prevention of Oxygen-Induced Retinopathy in a Rat Model |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2021 | ||
| 500 | |a Date Revised 24.02.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Given the complexity of oxygen-induced retinopathy (OIR), we tested the hypothesis that combination therapies and modes of administration would synergistically optimize efficacy for prevention of OIR. Newborn rats were exposed to neonatal intermittent hypoxia (IH) from the first day of life (P0) until P14 during which they received: (1) oral glutathione nanoparticles (nGSH) with topical ocular phosphate buffered saline (PBS); (2) nGSH with topical ocular Acuvail (ACV); (3) oral coenzyme Q10 (CoQ10) + ACV; (4) oral omega 3 polyunsaturated fatty acids (n-3 PUFAs) + ACV; (5) CoQ10 + n-3 PUFAs + PBS; or (6) CoQ10 + n-3 PUFAs + ACV. Treated groups raised in room air (RA) served as controls. At P14, pups were placed in RA with no treatment until P21. Retinal vascular pathology, ocular angiogenesis biomarkers, histopathology, and morphometry were determined. All combination treatments in IH resulted in the most beneficial retinal outcomes consistent with suppression of angiogenesis growth factors during reoxygenation/reperfusion and no significant adverse effects on somatic growth. nGSH + PBS also reversed IH-induced retinopathy, but had negative effects on growth. Simultaneously targeting oxidants, inflammation, and poor growth mitigates the damaging effects of neonatal IH on the developing retina. Therapeutic synergy with combination delivery methods enhance individual attributes and simultaneously target multiple pathways involved in complex diseases such as OIR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a coenzyme Q10 | |
| 650 | 4 | |a glutathione nanoparticles | |
| 650 | 4 | |a insulin-like Growth Factor-I | |
| 650 | 4 | |a ketorolac | |
| 650 | 4 | |a n-3 polyunsaturated fatty acids | |
| 650 | 4 | |a neonatal intermittent hypoxia | |
| 650 | 4 | |a oxygen-induced retinopathy | |
| 650 | 4 | |a vascular endothelial growth factor | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Cai, Charles L |e verfasserin |4 aut | |
| 700 | 1 | |a Siddiqui, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agrosa, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Zangaladze, Anano |e verfasserin |4 aut | |
| 700 | 1 | |a Mustafa, Ghassan |e verfasserin |4 aut | |
| 700 | 1 | |a Qadri, Areej |e verfasserin |4 aut | |
| 700 | 1 | |a Duggan, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Aranda, Jacob V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nutrients |d 2009 |g 12(2020), 7 vom: 03. Juli |w (DE-627)NLM206140738 |x 2072-6643 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:7 |g day:03 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/nu12071980 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 7 |b 03 |c 07 | ||